Authors
Latest:
Dr Jonasch on the Preliminary Efficacy of NKT-2152 in Advanced ccRCCEric Jonasch, MD, discusses preliminary findings from a trial investigating NKT-2152 in previously treated advanced clear cell renal cell carcinoma.
Latest:
Renal Cell Carcinoma: Future Evolutions in CareShared insight on the evolving state of renal cell carcinoma management and hope for future growth in the treatment landscape.
Latest:
Dr. Klein on the Rationale to Evaluate VERU-111 in mCRPCEric Klein, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.
Latest:
Dr. Larsen Discusses Outcomes for AYA ALL PatientsDr. Eric Larsen, from the Maine Children's Cancer Program, Discusses Outcomes for AYA Patients With Acute Lymphoblastic Leukemia
Latest:
Dr. Liu on Medical Advancements for Neuroendocrine TumorsEric Liu, MD, FACS, surgeon, neuroendocrine tumors, Rocky Mountain Cancer Centers, discusses some of the most recent medical advancements in the field of neuroendocrine tumors.
Latest:
Dr. Horwitz on the Evolution of Radiation Therapy in Prostate CancerEric M. Horwitz, MD, FABS, FASTRO, discusses the evolution of radiation therapy in prostate cancer.
Latest:
Dr. Ostertag on Emerging CAR T Product for MyelomaEric M. Ostertag, MD, PhD, chief executive officer, Poseida Therapeutics, Inc., discusses an emerging CAR T stem cell memory product for patients with relapsed/refractory multiple myeloma.
Latest:
Dr. Padron on the SRSF2 Mutation in MDS and CMMLEric Padron, MD, discusses the SRSF2 mutation in patients with MDS and CMML.
Latest:
Dr. Pujade-Lauraine on the AURELIA Bevacizumab TrialDr. Eric Pujade-Lauraine, from Université de Paris Descartes, France, on the AURELIA Bevacizumab Trial for Platinum-Resistant Ovarian Cancer.
Latest:
Dr. Nadler on the Impact of Immunotherapy in Squamous NSCLCEric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the impact of immunotherapy in squamous non–small cell lung cancer.
Latest:
Dr. Shinohara on Pairing SBRT With Immunotherapy in Prostate CancerEric Shinohara, MD, MSCI, discusses the potential to combine stereotactic body radiotherapy with immunotherapy in prostate cancer.
Latest:
Dr. Smith Discusses CAR T Cell Persistence in MyelomaEric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric antigen receptor (CAR) T cell persistence in patients with multiple myeloma.
Latest:
Dr Winer on the Rationale for the TakeAim Leukemia Trial in Mutated AMLEric Winer, MD, discusses the rationale for the phase 1/2a TakeAim Leukemia trial of emavusertib in patients with R/R FLT3- and spliceosome-mutated AML.
Latest:
Dr. Wong Discusses Recent Negative Trials in GlioblastomaEric T. Wong, MD, associate professor of neurology at Harvard Medical School and co-director of the Brain Tumor Center at Beth Israel Deaconess Medical Center, discusses recent negative trials in glioblastoma.
Latest:
Dr Vallieres on the Role of Induction Therapy on Surgical Candidacy in Lung CancerEric Vallieres, MD, FRCSC, discusses the impact of induction therapy on surgical candidacy and operative complexity in patients with thoracic malignancies.
Latest:
Dr. Van Cutsem on Primary Findings from the SPOTLIGHT and GLOW Trials in Metastatic Gastric CancerEric Van Cutsem, MD, PhD, discusses primary efficacy and safety findings from the phase 3 SPOTLIGHT and GLOW trials investigating the monoclonal antibody zolbetuximab in metastatic gastric cancer.
Latest:
Dr. Whitman on Expanding the Benefit of Immunotherapy in Solid TumorsEric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses ways to expand the benefit of immunotherapy in non-immunogenic solid tumors.
Latest:
Rehabilitation Should Be Part of Cancer TreatmentRehabilitation is medical care that cancer patients should expect and that it should be delivered by trained rehabilitation professionals: physiatrists, physical therapists, occupational therapists, or speech language pathologists.
Latest:
Early Promise of Radiation Plus PCV in Patients With Low-Grade GliomaErica Bell, PhD, assistant professor-Clinical, Ohio State University Comprehensive Cancer Center, discusses a mutational analysis examining radiation therapy plus procarbazine, CCNU, and vincristine (PCV) as a potential treatment for patients with high-risk, low-grade glioma.
Latest:
Chasing Survival Benefit With Novel Systemic Strategies in Early-Stage NSCLCKaushal Parikh, MD, MBBS, highlights ongoing research exploring systemic approaches in early-stage non¬–small cell lung cancer and shares where future efforts are headed.
Latest:
Ongoing Research and Unmet Needs in Patients With Breast Cancer and ESR1 MutationsDrs Mayer and Kalinsky conclude their discussion with a look at agents in development and unmet needs for patients with breast cancer and ESR1 mutations.
Latest:
Dr. Blok on Results of Adjuvant Letrozole Study in Breast CancerErik J. Blok, MD, Department of Medical Oncology at Leiden University Medical Center, discusses the duration of adjuvant endocrine therapy. Blok claims that there is no breast cancer survival benefit in extending adjuvant letrozole treatment from 2.5 to 5 years.
Latest:
Dr. Castle on Minimally Invasive Surgical Approaches in RCCErik P. Castle, MD, discusses minimally invasive surgical approaches in renal cell carcinoma.
